transmembrane protein 97Genealiases: MAC30 · S2R · sigma2R
Q-omics provides the consensus-scored TMEM97 profile across patient tissues and cancer cell-line models. TMEM97 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TMEM97 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, TMEM97 RNA expression shows 26,607 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, COAD, and LSCC as cancer lineages where TMEM97 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM97 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM97 survival associations across molecular data types. TMEM97 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM97 RNA expression–survival associations across cancer types. High TMEM97 expression shows unfavorable associations in KIRP, ACC, SKCM, LIHC, MESO and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TMEM97 RNA expression.
This table summarizes TMEM97 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM97. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM97 shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, BRCA, UCEC and BLCA. The COAD box plot shows higher TMEM97 RNA expression in tumor versus normal tissue (log2 FC = +1.947, t-test p < 0.001).
This table shows molecular features associated with TMEM97 in patient tissues and cancer cell lines. In patient samples, TMEM97 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM97 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
